186 related articles for article (PubMed ID: 38553687)
1. Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia- a case series.
Mølgaard SN; Nielsen MØ; Roed K; Nielsen J
BMC Psychiatry; 2024 Mar; 24(1):240. PubMed ID: 38553687
[TBL] [Abstract][Full Text] [Related]
2. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.
Bogers JPAM; Hambarian G; Walburgh Schmidt N; Vermeulen JM; de Haan L
Schizophr Bull; 2023 Jan; 49(1):11-23. PubMed ID: 36200866
[TBL] [Abstract][Full Text] [Related]
4. Mental Health Staff's Perspectives on Tapering of Antipsychotic Medication: A Focus Group Study.
Roed K; Buus N; Nielsen J; Christensen PS; Midtgaard J
Qual Health Res; 2023 Nov; 33(13):1165-1176. PubMed ID: 37710394
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
6. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis.
Ostuzzi G; Vita G; Bertolini F; Tedeschi F; De Luca B; Gastaldon C; Nosé M; Papola D; Purgato M; Del Giovane C; Correll CU; Barbui C
Lancet Psychiatry; 2022 Aug; 9(8):614-624. PubMed ID: 35753323
[TBL] [Abstract][Full Text] [Related]
7. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
[TBL] [Abstract][Full Text] [Related]
8. Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose.
Liu CC; Hsieh MH; Chien YL; Liu CM; Lin YT; Hwang TJ; Hwu HG
Eur Psychiatry; 2023 Aug; 66(1):e66. PubMed ID: 37578111
[TBL] [Abstract][Full Text] [Related]
9. An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders.
Crellin NE; Priebe S; Morant N; Lewis G; Freemantle N; Johnson S; Horne R; Pinfold V; Kent L; Smith R; Darton K; Cooper RE; Long M; Thompson J; Gruenwald L; Freudenthal R; Stansfeld JL; Moncrieff J
BMC Psychiatry; 2022 Mar; 22(1):185. PubMed ID: 35291964
[TBL] [Abstract][Full Text] [Related]
10. Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.
Liu CC; Takeuchi H
CNS Drugs; 2020 Feb; 34(2):117-126. PubMed ID: 31741178
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of the Need for Guideline Recommendations; Slow Tapering vs. Maintenance Dose in Long-Term Antipsychotic Treatment: 2022.
Potla S; Al Qabandi Y; Nandula SA; Boddepalli CS; Gutlapalli SD; Lavu VK; Abdelwahab Mohamed Abdelwahab R; Huang R; Hamid P
Cureus; 2023 Feb; 15(2):e34746. PubMed ID: 36777974
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
14. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
Winter-van Rossum I; Weiser M; Galderisi S; Leucht S; Bitter I; Glenthøj B; Hasan A; Luykx J; Kupchik M; Psota G; Rocca P; Stefanis N; Teitelbaum A; Bar Haim M; Leucht C; Kemmler G; Schurr T; ; Davidson M; Kahn RS; Fleischhacker WW
Lancet Psychiatry; 2023 Mar; 10(3):197-208. PubMed ID: 36716759
[TBL] [Abstract][Full Text] [Related]
16. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
[TBL] [Abstract][Full Text] [Related]
17. Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design.
Liu CC; Hsieh MH; Chien YL; Liu CM; Lin YT; Hwang TJ; Hwu HG
Early Interv Psychiatry; 2022 Feb; 16(2):178-185. PubMed ID: 33751764
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
[TBL] [Abstract][Full Text] [Related]
19. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis.
Kishi T; Ikuta T; Matsui Y; Inada K; Matsuda Y; Mishima K; Iwata N
Psychol Med; 2019 Apr; 49(5):772-779. PubMed ID: 29909790
[TBL] [Abstract][Full Text] [Related]
20. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
